Document is current
Any future updates will be listed below
-
Authors
Santoro, Claudia https://orcid.org/0000-0003-4547-0500
Servedio, Mariachiara
Diana, Maria Cristina
Russo, Irene
Arkhangelskaya, Elena
Piccolo, Gianluca
Santangelo, Andrea
Mastronuzzi, Angela
Cacchione, Antonella
Hachem, May El
Russo, Carmela
Cirillo, Mario
Cecconi, Ilaria
Grasso, Antonio
Loiotine, Mariateresa
Santoro, Nicola
Resta, Mariachiara
De Meco, Carmela
Soddu, Consolata
Spreafico, Eugenia
Rossi, Bartolomeo
Fossati, Chiara
Leoni, Chiara
Perrotta, Silverio
Perillo, Teresa
-
Funding
Funding for this research was provided by:
Università degli Studi della Campania Luigi Vanvitelli
- License Information
-
More Information
Article History
Received: 13 June 2025
Accepted: 2 August 2025
First Online: 13 August 2025
Declarations
:
: C.S. received payment for scientific consultation and speaker honoraria from Alexion, AstraZeneca Rare Disease; participated on a data safety monitoring/advisory board for Alexion, AstraZeneca Rare Disease; received payment for scientific consultation from IQVIA and Atheneum; and held a leadership or fiduciary role for ANF patient advocacy. T.P. received payment for scientific consultation and speaker honoraria from Alexion, AstraZeneca Rare Disease; and participated on an advisory board for Alexion, AstraZeneca Rare Disease. A.M. received speaker honoraria from Alexion, AstraZeneca Rare Disease and participated on an advisory board for Ipsen. C.L. participated in the SeluPASS steering committee. All the other authors declare no conflict of interest.
: This study was approved by the territorial Ethics Committee of the Polyclinic of Bari, Italy, on April 24, 2024, and conducted in accordance with the Helsinki Declaration, Good Clinical Practice guidelines, and all applicable laws and regulations.
: Written informed consent to participate was obtained from patients aged 18 years, and from parents/legal guardians of patients aged < 18 years.
: Not applicable.
